Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 - Key Players Are Eli Lilly, Bristol-Myers Squibb, Pfizer, and AstraZeneca - ResearchAndMarkets.com

DUBLIN--()--The "Cognitive Impairment Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

The total number of products under development for CIAS, dementia, mild cognitive impairment and Alzheimer's disease is 33, 109, 35 and 645, respectively. Key companies operating in these pipelines include Eli Lilly and Co., Bristol-Myers Squibb, Pfizer and AstraZeneca.

The majority of products under development for these disorders are small molecules, due to their ability to cross the blood-brain barrier and their proven commercial success in this area. In addition, the majority of products are neuromodulators, impacting the dopaminergic, serotonergic and glutamatergic systems. There is diversity within each indication in terms of molecule type and molecular targets.

This report provides an overview of the pipeline landscape for cognitive impairment disorders. It comprehensively documents therapeutics under development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

Some of the companies mentioned in this report include:

  • AB Science SA
  • AbbVie Inc
  • AstraZeneca Plc
  • Aucta Pharmaceuticals LLC
  • Avineuro Pharmaceuticals Inc
  • CereSpir Inc
  • CHA Bio & Diostech Co Ltd
  • CohBar Inc
  • Connexios Life Sciences Pvt Ltd
  • Cypralis Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Dongkook Pharmaceutical Co Ltd
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • Echo Pharmaceuticals BV
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Epigen Biosciences Inc
  • GlaxoSmithKline Plc
  • Golden Biotechnology Corp
  • Grifols SA
  • ID Pharma Co Ltd
  • Immungenetics AG
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Microlin Bio Inc
  • ModGene Pharma LLC
  • Octapharma AG
  • Oryzon Genomics SA
  • Otsuka Holdings Co Ltd
  • Ovensa Inc
  • Prevacus Inc
  • ProMIS Neurosciences Inc
  • Voyager Therapeutics Inc

Key Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/s7nkkq/cognitive?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery